pharma-software
(5)
P360 and the Art of Getting Through
Pharma has plenty to say and a complicated way of saying it. P360 puts the paperwork behind the conversation, connecting approved content, commercial data, and the phone already in a doctor’s pocket.
Pep Gubau Bet on AI Before Pharma Wanted to Hear About It
A two-week internship taught him what he did not want. Four decades, two exits and one stubborn bet later, Pep Gubau is still trying to make industrial data useful where every decision needs a paper trail.
Enjamb
Enjamb (YC P26) builds full-stack AI agents for biopharma R&D that run a drug program from discovery through FDA approval. Its agents sit on top of legacy pharma systems - Benchling, Veeva, Medidata, SAS - with no migration, doing the work across clinical evidence, trial design, statistical programming, and regulatory submissions while keeping a visible source-to-submission trail. Founded in 2025 by Rayan Mubarak and Maadhav Deekshitha, the San Francisco company raised a $650K pre-seed and says its platform was used by 500+ employees at major pharma firms within weeks of launch.
MetaCell
MetaCell is a life-science software company staffed by scientists and software engineers who turn messy neuroscience and biology data - microscopy, MRI, EEG, electrophysiology, biologically accurate simulations - into usable, shareable, enterprise-grade online tools. Founded by the trio behind the OpenWorm project, MetaCell builds custom scientific software, cloud workspaces, and data pipelines for pharma companies and top research institutions including Johnson & Johnson, Pfizer, Biogen, Eisai, the Allen Institute, the Chan Zuckerberg Initiative, and universities like Princeton, Yale, and UCL.
Mike Stapleton
Mike Stapleton is the Chief Business Officer of QbDVision, the Austin-based software company building a Digital CMC platform for pharma and biotech. He spent three decades moving between the lab bench, the boardroom, and the consulting deck - senior scientist at BP, COO at Accelrys, leader at Life Technologies, PerkinElmer, Merck, Microsoft, and Accenture - before joining QbDVision's board and then stepping in to run its commercial strategy. His argument is contrarian for a software executive: the bottleneck in drug development is not the platform, it is the people willing to standardize how an industry handles its data.